Results 121 to 130 of about 160,452 (346)

A 2‐Part, Open‐Label, Phase 1 Bioequivalence and Food‐Effect Study of Ubrogepant in Healthy Adult Participants

Clinical Pharmacology in Drug Development, EarlyView.
Abstract This Phase 1 study of ubrogepant was conducted to establish the bioequivalence (BE) of the 50‐ and 100‐mg to‐be‐marketed (TBM) tablet formulations with the clinical trial (CT) 100‐mg tablet formulation and evaluate the food effect on the bioavailability of the 100‐mg TBM tablet. This 2‐part study enrolled healthy participants aged 18‐45 years.
Ramesh Boinpally, Joel M. Trugman
wiley   +1 more source

Pharmacokinetics, Bioequivalence, and Safety Studies of Crisaborole Ointment in Healthy Chinese Subjects

Clinical Pharmacology in Drug Development, EarlyView.
Abstract The aim of this study was to evaluate the bioequivalence and safety of a single application of crisaborole ointment to test formulation and reference formulation in healthy subjects under fasting conditions. A total of 32 subjects were included and divided into 2 groups (test‐reference; reference‐test).
Yanchao Wang, Xiaofei Zhao, Taixin Wang, Luning Xiong, Xiujuan Liu, Jing Pan, Wen Yin, Chao Zhang, Jining Dong, Kexin Zhao   +9 more
wiley   +1 more source

Taste Profile and Relative Bioavailability of Tovorafenib Powder for Oral Suspension and Food Effect of the Tovorafenib Tablet in Healthy Participants

Clinical Pharmacology in Drug Development, EarlyView.
Abstract A pediatric‐friendly powder for oral suspension (PfOS) of tovorafenib, a type II RAF inhibitor, was developed for patients with difficulty swallowing tablets. This open‐label, randomized, phase 1 study (QSC205140) evaluated the taste/palatability of PfOS formulations (n = 12), the relative bioavailability of the PfOS versus tablet formulation,
Yang Zhang, Mike Preigh, Jing Wang, Eleni Venetsanakos, Yujin Wang, Elly Barry, Don Corson   +6 more
wiley   +1 more source

Cardiac sarcoidosis treated with nonsteroidal immunosuppressive therapy

International Journal of Cardiology: Heart & Vasculature
Background: Nonsteroidal immunosuppressive therapy is a potential therapeutic strategy for cardiac sarcoidosis. However, it is not recommended as an established treatment option.
Kenichiro Suwa, Yoshihisa Naruse, Takeru Nabeta, Takeshi Kitai, Tatsunori Taniguchi, Kenji Yoshioka, Hidekazu Tanaka, Takahiro Okumura, Yuichi Baba, Yuya Matsue, Yuichiro Maekawa   +10 more
doaj  

Inhibition of a major NAD(P)-linked oxidoreductase from rat liver cytosol by steroidal and nonsteroidal anti-inflammatory agents and by prostaglandins. [PDF]

, 1983
T.M. Penning, Paul Talalay
openalex   +1 more source

Diclofenac Detection via Inner‐Filter Effect Using Pyridine‐Modified Triphenylene

ChemPlusChem, EarlyView.
The synthesis of hexa‐pyridine triphenylene derivatives via Suzuki‐coupling reaction and their application toward the sensing of diclofenac have been studied for the first time. The 3PY and 4PY are selective for diclofenac over the other commonly prescribed pharmaceuticals and hormones tested. Triphenylene derivatives 3PY (2,3,6,7,10,11‐hexa(pyridine‐3‐
Navdeep Kajal, Amar Raj, Rajendhraprasad Tatikonda, Jan Lundell, Matti Haukka   +4 more
wiley   +1 more source

Prescribing Exercise for Chronic Pain Management [PDF]

, 2019
In light of the opioid crisis, practitioners are looking for alternative ways to effectively treat pain. Utilizing exercise modalities as a method of pain management is becoming increasingly popular and more research is being done in this area than ever ...
Hettinger, Katie
core   +1 more source

Implementing Pre‐Emptive Pharmacogenetics: Impact of Early Pharmacogenetic Screening in a Pediatric Oncology Cohort of 1,151 Subjects

Clinical Pharmacology &Therapeutics, EarlyView.
In pediatric oncology, pharmacogenetic guidelines are underutilized and the potential impact of pre‐emptive pharmacogenetic screening remains largely unexplored despite this field's need for individualized approaches. While comprehensive pharmacogenetic guidelines are not yet available for all anticancer drugs, evidence‐based recommendations exist for ...
Emma C. Bernsen, Eugène T.P. Verwiel, Maaike van der Lee, Jesse J. Swen, Marcel Santoso, Leiah J. Brigitha, Rick Admiraal, Bastiaan B.J. Tops, Alwin D.R. Huitema, Patrick Kemmeren, Jayne Y. Hehir‐Kwa, Lidwien M. Hanff, Meta H.M. Diekstra   +12 more
wiley   +1 more source

Changes in kidney function in a population with essential hypertension in real life settings [PDF]

, 2017
Introduction. Hypertension has been identified as one of the commonest modifiable determinants for chronic kidney disease progression. A variety of antihypertensive drugs are available and their effect on kidney function has been investigated by a ...
Haidich, Anna-Bettina, Lasaridis, Anastasios N., Mark, Patrick B., Pikilidou, Maria I., Ptinopoulou, Anastasia G., Tziolas, Ioannis M., Zebekakis, Pantelis E.   +6 more
core  

Prevalence of Actionable Pharmacogenetic Genotype Frequencies, Cautionary Medication Use, and Polypharmacy in Community‐Dwelling Older Adults

Clinical Pharmacology &Therapeutics, EarlyView.
Older adults (65 years and over) frequently manage complex medication regimens and are vulnerable to adverse drug reactions and treatment inefficacies, some of which could be preventable with pharmacogenetics (PGx)‐guided prescribing. This study examined the prevalence of actionable PGx genotypes (i.e., those linked to a guideline that recommends a ...
Chad A. Bousman, Ankita Narang, Ziad Al Bkhetan, Robyn L. Woods, Suzanne G. Orchard, Alice J. Owen, Michelle A. Fravel, Julia Gilmartin‐Thomas, Joanne Ryan, Peter D. Fransquet, Rory Wolfe, Chenglong Yu, John J. McNeil, Paul Lacaze, Michael E. Ernst   +14 more
wiley   +1 more source